PE89199A1 - Composicion farmaceutica de tiazolidinadiona y un inhibidor de alfa glucosidasa para el tratamiento de la diabetes - Google Patents

Composicion farmaceutica de tiazolidinadiona y un inhibidor de alfa glucosidasa para el tratamiento de la diabetes

Info

Publication number
PE89199A1
PE89199A1 PE1998000536A PE00053698A PE89199A1 PE 89199 A1 PE89199 A1 PE 89199A1 PE 1998000536 A PE1998000536 A PE 1998000536A PE 00053698 A PE00053698 A PE 00053698A PE 89199 A1 PE89199 A1 PE 89199A1
Authority
PE
Peru
Prior art keywords
treatment
diabetes
tiazolidinadiona
pharmaceutical composition
glucosidase inhibitor
Prior art date
Application number
PE1998000536A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712865.6A external-priority patent/GB9712865D0/en
Priority claimed from GBGB9806708.5A external-priority patent/GB9806708D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PE89199A1 publication Critical patent/PE89199A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
PE1998000536A 1997-06-18 1998-06-18 Composicion farmaceutica de tiazolidinadiona y un inhibidor de alfa glucosidasa para el tratamiento de la diabetes PE89199A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712865.6A GB9712865D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806708.5A GB9806708D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
PE89199A1 true PE89199A1 (es) 1999-10-23

Family

ID=26311746

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000536A PE89199A1 (es) 1997-06-18 1998-06-18 Composicion farmaceutica de tiazolidinadiona y un inhibidor de alfa glucosidasa para el tratamiento de la diabetes

Country Status (24)

Country Link
EP (1) EP0975343A1 (no)
JP (1) JP2001523271A (no)
KR (1) KR20010013845A (no)
CN (1) CN1274282A (no)
AP (1) AP9901720A0 (no)
AR (2) AR013352A1 (no)
AU (1) AU8799998A (no)
BG (1) BG103966A (no)
BR (1) BR9810186A (no)
CA (1) CA2294134A1 (no)
CO (1) CO4940453A1 (no)
DZ (1) DZ2519A1 (no)
EA (1) EA200000040A1 (no)
IL (1) IL133138A0 (no)
MA (1) MA26510A1 (no)
NO (1) NO996270L (no)
NZ (1) NZ501345A (no)
OA (1) OA11631A (no)
PE (1) PE89199A1 (no)
PL (1) PL337577A1 (no)
SK (1) SK179499A3 (no)
TR (1) TR199903072T2 (no)
UY (1) UY25051A1 (no)
WO (1) WO1998057635A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064892A2 (en) 1999-04-23 2000-11-02 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
CA2442917C (en) 2001-04-04 2011-02-01 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
DE60233655D1 (de) 2001-04-04 2009-10-22 Ortho Mcneil Janssen Pharm R und retinoid x rezeptorenmodulatoren
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
JP2004067575A (ja) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
CN101121004B (zh) * 2006-08-08 2010-07-21 鲁南制药集团股份有限公司 含有胰岛素增敏剂和米格列醇的药物组合物
CN101584688B (zh) * 2008-05-24 2010-11-10 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物
CN101584705B (zh) * 2008-05-24 2010-10-27 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0601001B1 (en) * 1991-08-26 1997-04-16 PHARMACIA & UPJOHN COMPANY Liquid food product containing 3-guanidinopropionic acid
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
EA200000040A1 (ru) 2000-08-28
CN1274282A (zh) 2000-11-22
JP2001523271A (ja) 2001-11-20
SK179499A3 (en) 2000-11-07
AR013352A1 (es) 2000-12-27
EP0975343A1 (en) 2000-02-02
PL337577A1 (en) 2000-08-28
CO4940453A1 (es) 2000-07-24
AR014881A1 (es) 2001-04-11
MA26510A1 (fr) 2004-12-20
NZ501345A (en) 2001-10-26
NO996270D0 (no) 1999-12-17
WO1998057635A1 (en) 1998-12-23
TR199903072T2 (xx) 2000-07-21
KR20010013845A (ko) 2001-02-26
BR9810186A (pt) 2000-08-08
AU8799998A (en) 1999-01-04
CA2294134A1 (en) 1998-12-23
AP9901720A0 (en) 1999-12-31
OA11631A (en) 2004-11-22
NO996270L (no) 1999-12-17
DZ2519A1 (fr) 2003-02-01
IL133138A0 (en) 2001-03-19
UY25051A1 (es) 2000-09-29
BG103966A (bg) 2000-07-31

Similar Documents

Publication Publication Date Title
PE83199A1 (es) Composicion farmaceutica de tiazolidinadiona y biguanida para el tratamiento de la diabetes
TR200102874T2 (tr) Heterosiklik i‡erikli bifenil AP2 ”nleyicileri ve metot.
UY25713A1 (es) Método para tratar diabetes empleando un inhibidor ap2 y combinación.
CY1105254T1 (el) Θepαπεια του διαβητη με θειαζολιδινδιονη, εκκριταγωγο ινσουλινης και διγουανιδιο
AR011829A1 (es) Combinaciones para diabetes de sulfonilurea-glitazona.
PE89199A1 (es) Composicion farmaceutica de tiazolidinadiona y un inhibidor de alfa glucosidasa para el tratamiento de la diabetes
PE104499A1 (es) Composicion farmaceutica de tiazolidindiona e insulina para el tratamiento de la diabetes
AR046210A1 (es) Preparacion solida
PE99499A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
PE99799A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
PE108199A1 (es) Composicion farmaceutica de tiazolidindiona y sulfonilurea
EA200300005A1 (ru) Соль тиазолидиндиона для лечения сахарного диабета
EA200300423A1 (ru) Производное тиазолидиндиона и его применение в качестве противодиабетического лекарственного средства
CO5150180A1 (es) Nueva composicion y uso liberacion modificada
ECSP982592A (es) Nuevo metodo de tratamiento v
ECSP982535A (es) Nuevo metodo de tratamiento (i)
ECSP982593A (es) Nuevo metodo de tratamiento vi
ES2174748B1 (es) Nueva sal de tiazolidindiona y sus polimorfos como agentes antidiabeticos y procedimiento para la obtencion de los mismos.
ECSP982534A (es) Nuevo metodo de tratamiento
ES2083319B1 (es) Monohidrato de clorhidrato de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil)-6-cloro-1,3-dihidro-2h-indol-2-ona.
UY26341A1 (es) Método para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condición asociada con diabetes.

Legal Events

Date Code Title Description
FC Refusal